| Identification | Back Directory | [Name]
alpha-yohimbine | [CAS]
131-03-3 | [Synonyms]
4-(2-amino-1-hydroxyethyl)-2-methoxyphenol hydrochloride(1:1)
methyl (16beta,17alpha,20alpha)-17-hydroxyyohimban-16-carboxylate | [EINECS(EC#)]
205-006-9 | [Molecular Formula]
C21H26N2O3 | [MOL File]
131-03-3.mol | [Molecular Weight]
354.443 |
| Chemical Properties | Back Directory | [Melting point ]
243-244° | [alpha ]
D19 -18° (pyridine); D19 -27° (abs alcohol) | [Boiling point ]
543.0±50.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
6.34(at 25℃) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
Rauwolscine is a selective α2-adrenoceptor antagonist that inhibits tumor growth and induces apoptosis[1]. | [Definition]
ChEBI: Rauwolscine is a methyl 17-hydroxy-20xi-yohimban-16-carboxylate. | [in vivo]
Rauwolscine (0.5 mg/kg, daily) reduces tumor growth by enhancing apoptosis and reducing cell proliferation in Balb/c female virgin mice[1].
Rauwolscine (i.v., 2.24 mg/kg) can significantly release lick-shock conflict responding in rats similar to the α agonist clonidine (0.022 mg/kg) and the benzodiazepine diazepam (0.5 mg/kg) [2].
| [References]
[1] A Bruzzone, et al. Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008 Oct;155(4):494-504. DOI:10.1038/bjp.2008.278
[2] S La Marca, et al. The alpha-2 antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock conflict paradigm following intravenous administration. Life Sci. 1994;54(10):PL179-84. DOI:10.1016/0024-3205(94)00556-7 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|